tetano
Editor, Senior Moderator
BMC Res Notes
. 2024 Jan 24;17(1):37.
doi: 10.1186/s13104-024-06695-x. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
Carson K L Lo[SUP] 1 2 [/SUP], Calvin K F Lo[SUP] 3 [/SUP], Adam S Komorowski[SUP] 4 5 [/SUP], Victor Leung[SUP] 3 6 [/SUP], Nancy Matic[SUP] 3 6 [/SUP], Susan McKenna[SUP] 7 [/SUP], Santiago Perez-Patrigeon[SUP] 8 [/SUP], Prameet M Sheth[SUP] 9 10 11 12 [/SUP], Christopher F Lowe[SUP] 3 6 [/SUP], Zain Chagla[SUP] 13 14 [/SUP], Anthony D Bai[SUP] 8 [/SUP]
Affiliations
Background: In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2.
Methods: A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status).
Results: Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (- 14.3%; 95% confidence interval (CI): - 32.6 to 4.0%), ICU admission (- 7.1%; 95%CI: - 20.6 to 6.3%), and mortality (- 7.1%; 95%CI: - 20.6 to 6.3%).
Conclusions: No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Keywords: Antibodies, Monoclonal; BA.2 subvariant; COVID-19; COVID-19 drug treatment; Omicron; SARS-CoV-2; Sotrovimab.
. 2024 Jan 24;17(1):37.
doi: 10.1186/s13104-024-06695-x. Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
Carson K L Lo[SUP] 1 2 [/SUP], Calvin K F Lo[SUP] 3 [/SUP], Adam S Komorowski[SUP] 4 5 [/SUP], Victor Leung[SUP] 3 6 [/SUP], Nancy Matic[SUP] 3 6 [/SUP], Susan McKenna[SUP] 7 [/SUP], Santiago Perez-Patrigeon[SUP] 8 [/SUP], Prameet M Sheth[SUP] 9 10 11 12 [/SUP], Christopher F Lowe[SUP] 3 6 [/SUP], Zain Chagla[SUP] 13 14 [/SUP], Anthony D Bai[SUP] 8 [/SUP]
Affiliations
- PMID: 38267971
- DOI: 10.1186/s13104-024-06695-x
Background: In vitro data suggested reduced neutralizing capacity of sotrovimab, a monoclonal antibody, against Omicron BA.2 subvariant. However, limited in vivo data exist regarding clinical effectiveness of sotrovimab for coronavirus disease 2019 (COVID-19) due to Omicron BA.2.
Methods: A multicentre, retrospective cohort study was conducted at three Canadian academic tertiary centres. Electronic medical records were reviewed for patients ≥ 18 years with mild COVID-19 (sequencing-confirmed Omicron BA.1 or BA.2) treated with sotrovimab between February 1 to April 1, 2022. Thirty-day co-primary outcomes included hospitalization due to moderate or severe COVID-19; all-cause intensive care unit (ICU) admission, and all-cause mortality. Risk differences (BA.2 minus BA.1 group) for co-primary outcomes were adjusted with propensity score matching (e.g., age, sex, vaccination, immunocompromised status).
Results: Eighty-five patients were included (15 BA.2, 70 BA.1) with similar baseline characteristics between groups. Adjusted risk differences were non-statistically significant between groups for 30-day hospitalization (- 14.3%; 95% confidence interval (CI): - 32.6 to 4.0%), ICU admission (- 7.1%; 95%CI: - 20.6 to 6.3%), and mortality (- 7.1%; 95%CI: - 20.6 to 6.3%).
Conclusions: No differences were demonstrated in hospitalization, ICU admission, or mortality rates within 30 days between sotrovimab-treated patients with BA.1 versus BA.2 infection. More real-world data may be helpful to properly assess sotrovimab's effectiveness against infections due to specific emerging COVID-19 variants.
Keywords: Antibodies, Monoclonal; BA.2 subvariant; COVID-19; COVID-19 drug treatment; Omicron; SARS-CoV-2; Sotrovimab.